findmyKOL
Clinical trialNCT00013585CompletedPhase 2Interventional

Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV Patients

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment127Cognition DisordersHIV Infections
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

A decrease in mental function often occurs in patients with HIV. Antiretroviral (ARV) drugs are used to treat this but are not entirely effective. Some other therapy could play a role. The drug selegiline in its pill form is used to treat Parkinson's disease, a serious brain disorder. It is believed this drug might protect the brain and repair some damage. This study will use this drug in a "patch" form, which has not been approved by the Food and Drug Administration (FDA), to see if it helps with decreased mental function in patients with HIV. The purpose of this study is to evaluate the use of selegiline transdermal system (STS) in the treatment of decreased mental function in patients with HIV.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • David Simpson, M.D.

    Department of Clinical Neurophysiology, Mount Sinai School of Medicine

    Study Chair
    clinicaltrials.gov ↗
  • Giovanni Schifitto, M.D.

    Department of Neurology, University of Rochester Medical Center

    Study Chair
    clinicaltrials.gov ↗
  • Ned Sacktor, M.D.

    Department of Neurology, Johns Hopkins University Bayview Medical Center

    Study Chair
    clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

15 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Ucla Care Center Crs

    Los Angeles, California, United States

  • Ucsd, Avrc Crs

    San Diego, California, United States

  • Univ. of Hawaii at Manoa, Leahi Hosp.

    Honolulu, Hawaii, United States

  • Cook County Hosp. Core Ctr.

    Chicago, Illinois, United States

  • Northwestern University Crs

    Chicago, Illinois, United States

  • Johns Hopkins Adult Aids Crs

    Baltimore, Maryland, United States

  • Massachusetts General Hospital Actg Crs

    Boston, Massachusetts, United States

  • Washington U Crs

    St Louis, Missouri, United States

  • Beth Israel Med. Ctr., Actu

    New York, New York, United States

  • Columbia Univ., Hiv Prevention and Treatment Medical Ctr.

    New York, New York, United States

  • Univ. of Rochester Actg Crs

    Rochester, New York, United States

  • Unc Aids Crs

    Chapel Hill, North Carolina, United States

  • Hosp. of the Univ. of Pennsylvania Crs

    Philadelphia, Pennsylvania, United States

  • the Miriam Hosp. Actg Crs

    Providence, Rhode Island, United States

  • University of Washington Aids Crs

    Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Selegiline →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
—
Primary completion
—
Completion
31 Dec 2005
Last update posted
1 Nov 2021
Registered enrollment
127
Registry id
NCT00013585
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.